HomeCompareUSRC vs ABBV

USRC vs ABBV: Dividend Comparison 2026

USRC yields 666666.64% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 USRC wins by $8.275232860974063e+34M in total portfolio value
10 years
USRC
USRC
● Live price
666666.64%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.275232860974063e+34M
Annual income
$82,727,917,858,541,760,000,000,000,000,000,000,000,000.00
Full USRC calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — USRC vs ABBV

📍 USRC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodUSRCABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, USRC + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
USRC pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

USRC
Annual income on $10K today (after 15% tax)
$56,666,664.78/yr
After 10yr DRIP, annual income (after tax)
$70,318,730,179,760,495,000,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, USRC beats the other by $70,318,730,179,760,495,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of USRC + ABBV for your $10,000?

USRC: 50%ABBV: 50%
100% ABBV50/50100% USRC
Portfolio after 10yr
$4.1376164304870313e+34M
Annual income
$41,363,958,929,270,880,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

USRC
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

USRC buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricUSRCABBV
Forward yield666666.64%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$8.275232860974063e+34M$102.3K
Annual income after 10y$82,727,917,858,541,760,000,000,000,000,000,000,000,000.00$24,771.77
Total dividends collected$8.275073123314078e+34M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: USRC vs ABBV ($10,000, DRIP)

YearUSRC PortfolioUSRC Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$66,677,364$66,666,664.44$11,550$430.00+$66.67MUSRC
2$415,506,623,421$415,435,278,640.91$13,472$627.96+$415506.61MUSRC
3$2,419,908,356,437,039$2,419,463,764,349,978.00$15,906$926.08+$2419908356.42MUSRC
4$13,171,695,887,171,070,000$13,169,106,585,229,683,000.00$19,071$1,382.55+$13171695887171.05MUSRC
5$67,004,916,327,364,430,000,000$66,990,822,612,765,170,000,000.00$23,302$2,095.81+$67004916327364432.00MUSRC
6$318,562,213,303,255,840,000,000,000$318,490,518,042,785,600,000,000,000.00$29,150$3,237.93+$318562213303255826432.00MUSRC
7$1,415,483,838,639,479,800,000,000,000,000$1,415,142,977,071,245,000,000,000,000,000.00$37,536$5,121.41+$1.41548383863948e+24MUSRC
8$5,878,129,006,183,836,000,000,000,000,000,000$5,876,614,438,476,492,000,000,000,000,000,000.00$50,079$8,338.38+$5.878129006183836e+27MUSRC
9$22,813,786,167,165,610,000,000,000,000,000,000,000$22,807,496,569,128,995,000,000,000,000,000,000,000.00$69,753$14,065.80+$2.281378616716561e+31MUSRC
10$82,752,328,609,740,630,000,000,000,000,000,000,000,000$82,727,917,858,541,760,000,000,000,000,000,000,000,000.00$102,337$24,771.77+$8.275232860974063e+34MUSRC

USRC vs ABBV: Complete Analysis 2026

USRCStock

Unisource Corporate Corporation provides third-party logistics (3PL) services and cloud-based logistics services. The company was incorporated in 1969 and is based in Miami, Florida.

Full USRC Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this USRC vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

USRC vs SCHDUSRC vs JEPIUSRC vs OUSRC vs KOUSRC vs MAINUSRC vs JNJUSRC vs MRKUSRC vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.